Lumakras (Sotorasib): A Detailed Look at Its Use in Non-Small Cell Lung Cancer

Understanding Lumakras (Sotorasib) for Non-Small Cell Lung Cancer (NSCLC) Lumakras, with the active ingredient sotorasib, is a targeted therapy medication prescribed for adults diagnosed with a specific type of non-small cell lung cancer (NSCLC). This cancer is characterized by a particular genetic mutation known as KRAS G12C. NSCLC is the most common form of lung cancer, and the KRAS G12C mutation, while less common than other KRAS mutations, presents a unique challenge in treatment. Lumakras offers a new avenue for patients whose cancer has progressed after prior treatments. It is an oral tablet, making it convenient for patients to take at home. How Lumakras Works: Targeting the KRAS G12C Mutation Lung cancer, particularly NSCLC, can be driven by genetic mutations that promote uncontrolled cell growth. The KRAS gene is one such gene, and when it undergoes a specific change, like the G12C mutation, it can lead to the development and progression of cancer. Lumakras is designed to specifically inhibit this mutated KRAS G12C protein. By blocking the activity of this abnormal protein, Lumakras helps to slow down or stop the growth of cancer cells. This targeted approach aims to be more effective and potentially have fewer side effects than traditional chemotherapy, which affects all rapidly dividing cells, including healthy ones. Indications and Usage Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. This means it is typically used after other treatments like chemotherapy or immunotherapy have been tried and have not been effective. The diagnosis of the KRAS G12C mutation is crucial and is usually determined through specific genetic testing of the tumor tissue. Dosage and Administration Lumakras is available as an oral tablet in two strengths: 120 milligrams (mg) and 320 mg. The standard dosage for treating NSCLC is 960 mg taken once daily. This typically translates to taking three 320-mg tablets or eight 120-mg tablets each day. It is essential to take Lumakras exactly as prescribed by your doctor. Do not chew, crush, or split the tablets. They should be swallowed whole. If you miss a dose, consult your doctor for guidance. Taking more than the prescribed dose can be harmful, and in case of overdose, immediate medical attention should be sought. Contact your doctor or America’s Poison Centers for advice. If symptoms are severe, call emergency services. Potential Side Effects Like all medications, Lumakras can cause side effects, ranging from mild to serious. It is important to be aware of these potential effects and discuss them with your healthcare provider. Common Mild Side Effects: Fatigue Nausea Diarrhea Decreased appetite Dry mouth Abdominal pain Vomiting Musculoskeletal pain Increased liver enzymes (detected through blood tests) Increased creatinine (detected through blood tests) Rash Cough Shortness of breath Swelling (e.g., in arms, legs, eyes, or testicles) Most mild side effects tend to resolve within a few days or weeks. However, if they become persistent or bothersome, seeking medical advice is recommended. Serious Side Effects: While less common, Lumakras can cause serious side effects that require immediate medical attention: Liver problems: Symptoms may include yellowing of the skin or eyes (jaundice), dark urine, or severe abdominal pain. Diarrhea: Severe or persistent diarrhea can lead to dehydration and electrolyte imbalances. Interstitial Lung Disease (ILD)/Pneumonitis: This is a serious lung condition that can cause inflammation and scarring of the lungs. Symptoms include new or worsening shortness of breath, cough, and fever. Heart problems: This can include heart failure or heart attack. Symptoms may involve chest pain, shortness of breath, or swelling in the legs and feet. Blood clots: Lumakras may increase the risk of blood clots, which can be life-threatening. Low levels of white or red blood cells: This can increase the risk of infection and anemia. Low levels of calcium or sodium in the blood: Electrolyte imbalances can cause various symptoms and require medical management. Allergic reactions: While rare, severe allergic reactions can occur. Symptoms of a mild allergic reaction might include flushing or rash. A severe reaction can involve swelling of the face, lips, tongue, or throat, leading to difficulty breathing. If you experience any signs of serious side effects, contact your doctor immediately. If you believe you are having a medical emergency, call 911 or your local emergency number. Drug Interactions Lumakras can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. It is crucial to inform your doctor about all medications, supplements, and herbal products you are currently taking. Specific interactions may occur with certain antacids, proton pump inhibitors, and other drugs that affect stomach acidity, as well as certain antifungal medications and St. John's Wort. Your doctor will assess these potential interactions and adjust your treatment plan accordingly. Pregnancy and Breastfeeding Lumakras is not recommended for use during pregnancy due to potential harm to the fetus. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose. If you become pregnant or think you might be pregnant while taking Lumakras, inform your doctor immediately. Regarding breastfeeding, it is generally advised to wait at least one week after your last dose of Lumakras before breastfeeding. Consult your doctor for personalized advice on this matter. Savings and Support Programs For patients concerned about the cost of Lumakras, financial assistance programs may be available. Discussing your concerns with

In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.